NovaBridge Biosciences/$NBP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NovaBridge Biosciences
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
Ticker
$NBP
Sector
Primary listing
Employees
30
Headquarters
Website
NBP Metrics
BasicAdvanced
$286m
-
-$0.92
1.74
-
Price and volume
Market cap
$286m
Beta
1.74
52-week high
$6.79
52-week low
$0.83
Average daily volume
1m
Financial strength
Current ratio
8.088
Quick ratio
7.906
Long term debt to equity
0.942
Total debt to equity
1.328
Profitability
EBITDA (TTM)
-94.201
Management effectiveness
Return on assets (TTM)
-24.90%
Return on equity (TTM)
-40.89%
Valuation
Price to book
1.23
Price to tangible book (TTM)
1.23
Price to free cash flow (TTM)
-11.48
Free cash flow yield (TTM)
-8.71%
Free cash flow per share (TTM)
-0.215
Growth
Earnings per share change (TTM)
236.90%
3-year earnings per share growth (CAGR)
-41.02%
What the Analysts think about NBP
Analyst ratings (Buy, Hold, Sell) for NovaBridge Biosciences stock.
NBP Financial Performance
Revenues and expenses
NBP Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for NovaBridge Biosciences stock?
NovaBridge Biosciences (NBP) has a market cap of $286M as of May 01, 2026.
What is the P/E ratio for NovaBridge Biosciences stock?
The price to earnings (P/E) ratio for NovaBridge Biosciences (NBP) stock is 0 as of May 01, 2026.
Does NovaBridge Biosciences stock pay dividends?
No, NovaBridge Biosciences (NBP) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next NovaBridge Biosciences dividend payment date?
NovaBridge Biosciences (NBP) stock does not pay dividends to its shareholders.
What is the beta indicator for NovaBridge Biosciences?
NovaBridge Biosciences (NBP) has a beta rating of 1.74. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.